In This Section

Program

Please note that this special conference will take place as an in-person event in Boston and will not live-stream content for virtual participation. The conference content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Sunday, September 28

monday, September 29

tuesday, September 30

wednesday, october 1

Sunday, September 28

REGISTRATION

3-9 p.m. | American Ballroom Foyer (4th Floor)

WELCOME AND Keynote lectures

5-6:30 p.m. | America Ballroom (4th Floor)

  • 5 p.m. | Welcome from Conference Cochairs
    David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
  • 5:10 p.m. | Comments from Lead Supporter
    Andrew Rakeman, The Lustgarten Foundation, Uniondale, New York
  • 5:25 p.m. | Altered pancreas function for detection and interception of localized pancreatic cancer
    Brian M. Wolpin, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 5:50 p.m. | Rising Star Keynote
    Ashley L. Kiemen, Johns Hopkins University of Medicine, Baltimore, Maryland
  • 6:10 p.m. | Discussion / Q&A

break

6:30-6:45 p.m. | American Ballroom Foyer (4th Floor)

plenary Session 1: Revolutionizing Early Diagnosis and Prevention

6:45-8:30 p.m. | America Ballroom (4th Floor)

Session Chair: Laura DeLong Wood, Johns Hopkins University School of Medicine, Baltimore, Maryland

  • 6:45 p.m. | Opportunities with understanding early pancreatic cancer
    Laura DeLong Wood
  • 7:10 p.m. | The earlier detection of pancreatic cancer and the role of AI and radiomics
    Elliot Fishman, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 7:30 p.m. | Florencia McAllister, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 7:50 p.m. | Developing successful strategies for the early detection of pancreatic adenocarcinoma
    Randall E. Brand, University of Pittsburgh, Pittsburgh, Pennsylvania
  • 8:10 p.m. | Discussion / Q&A

OPENING RECEPTION

8:30-10:30 p.m. | Essex Ballroom (3rd Floor)

Monday, September 29

CONTINENTAL BREAKFAST

7-8 a.m. | America Foyer and Huntington AB

cochair highlights

8-8:30 a.m. | America Ballroom (4th Floor)

  • 8 a.m. | How the biology of pancreatic cancer is leading to new therapies
    Edna Cukierman, Fox Chase Cancer Center, Philadelphia, Pennsylvania
  • 8:20 a.m. | Daily Preview

Plenary Session 2: Spotlight on New Drug Development

8:30-10:15 a.m. | America Ballroom (4th Floor)

Session Chair: Eileen M. O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York

  • 8:35 a.m. | KRAcking open KRAS: Thoughts on KRAS drug development
    David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 8:55 a.m. | CRISPR-drug combinatorial screening identifies effective combination treatments for CDKN2A/MTAP-null PDAC
    Kathleen M. Mulvaney, Virginia Polytechnic Institute and State University, Washington, DC
  • 9:15 a.m. | Novel insights and therapies for BRCA-related pancreatic cancer
    Kim A. Reiss, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
  • 9:35 a.m. | Tumor cell plasticity, stromal rewiring, and clonal T cell expansion define response and resistance to combined PARP and PD-1 blockade (POLAR) in pancreatic cancer*
    Marc Hilmi, Memorial Sloan Kettering Cancer Center, New York, New York
  • 9:40 a.m. | Altered RNA splicing drives pancreatic cancer by mimicking chromosome deletions*
    Natasha Pinto Medici, Yale University, New Haven, Connecticut
  • 9:45 a.m. | p53 licenses transcriptional regulation by TEAD to dictate cell fate in pancreatic ductal adenocarcinoma*
    Cole Martin, University of North Carolina, Chapel Hill, North Carolina
  • 9:50 a.m. | Discussion / Q&A

break

10:15-10:45 a.m. | American Ballroom Foyer (4th Floor)

PLENARY Session 3: Biology of Pancreatic Cancer Progression

10:45 a.m.-12:30 p.m. | America Ballroom (4th Floor)

Session Chair: Marina Pasca di Magliano, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan

  • 10:50 a.m. | The dynamic life of stress granules in pancreatic cancer: A tale of obesity, the cell cycle, and therapeutic resistance
    Elda Grabocka, Thomas Jefferson University, Philadelphia, Pennsylvania
  • 11:10 a.m. | Identifying immune vulnerabilities in pancreatic cancer
    Dieter Saur, Technical University of Munich, Germany
  • 11:30 a.m. | Mutant GNAS drives an indolent phenotype in IPMN by modulating the glycome
    Kathleen E. DelGiorno, Vanderbilt University School of Medicine, Nashville, Tennessee
  • 11:50 a.m. | Linking reactive oxygen species and neutrophil extracellular traps formation to pancreatic ductal adenocarcinoma progression*
    Angisha Basnet, West Virginia University School of Medicine, Morgantown, West Virginia
  • 11:55 a.m. | Fibroblast STAT3 activation drives organ-specific premetastatic niche formation*
    Emily Lasse-Opsahl, University of Michigan Medical School, Ann Arbor, Michigan
  • 12 p.m. | Chemotherapy-associated liver damage accelerates pancreatic cancer liver metastasis*
    Nikki Lytle, Medical College of Wisconsin, Milwaukee, Wisconsin
  • 12:05 p.m. | Discussion / Q&A

lunch on own/free time

12:30-2:30 p.m.

Plenary Session 4: Harnessing the Immune System to Treat Pancreatic Cancer

2:30-4:15 p.m. | America Ballroom (4th Floor)

Session Chair: Gregory L. Beatty, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

  • 2:35 p.m. | Cryptic antigens: Novel targets for TCR-based therapies in pancreas cancer
    William Freed-Pastor, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 2:55 p.m. | Modulating the immunosuppressive stroma: bringing antitumor immune cells back into the game
    Debora Barbosa Vendramini-Costa, Michigan State University, Detroit, Michigan
  • 3:15 p.m. | Leveraging functional screens to engineer more potent T cells for solid tumors
    Julia Carnevale, University California, San Francisco, California
  • 3:35 p.m. | Early bystander effect of vaccine boosting of CAR T cells reinvigorates endogenous anti-tumor T cell immunity to regress pancreatic cancer*
    Leyuan Ma, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
  • 3:40 p.m. | Myofibroblast programming blocks differentiation of immune enhancing fibroblastic reticular cells in pancreatic cancer*
    Andrew Gunderson, The Ohio State University Wexner Medical Center, Columbus, Ohio
  • 3:45 p.m. | FAK inhibition improves CD40 agonist immunotherapy response and reduces MAPK signaling in pancreatic ductal adenocarcinoma*
    Anna Thickens, University of Pennsylvania, Philadelphia, Pennsylvania
  • 3:50 p.m. | Discussion / Q&A

Poster session a/reception

4:30-7 p.m. | Essex Ballroom (3rd Floor)

Tuesday, September 30

CONTINENTAL BREAKFAST

7-8 a.m. | America Foyer and Huntington AB

cochair highlights

8-8:30 a.m. | America Ballroom (4th Floor)

  • 8 a.m. | How the biology of pancreatic cancer is leading to new therapies
    Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 8:20 a.m. | Daily Preview

Plenary Session 5: Translational Advances to Dissect Pancreatic Cancer Treatment Response

8:30-10:15 a.m. | America Ballroom (4th Floor)

Session Chair: Manuel Hidalgo, NYU Langone Health Perlmutter Cancer Center, New York, New York

  • 8:35 a.m. | Targeting KRAS beyond G12C in pancreatic cancer
    Ignacio Garrido-Laguna, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
  • 8:55 a.m. | Pancreatic cancer phenotypes
    Faiyaz Notta, UHN Princess Margaret Cancer Center, Toronto, ON, Canada
  • 9:15 a.m. | Targeting the oncogenic state of RAS in pancreatic cancer with tri-complex inhibitors
    Mallika Singh, Revolution Medicines, Redwood City, California
  • 9:35 a.m. | Integrative proteogeonomic profiling of PDAC reveals updated epithelial subtypes and cross-omic predictors of survival*
    Ferris Nowlan, University of Toronto, Toronto, ON, Canada
  • 9:40 a.m. | EMT-associated integrin signaling drives resistance to RAS-GTP inhibition in pancreatic cancer*
    Joshua Choe, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 9:45 a.m. | TNFR-MK2 signaling drives autophagy and resistance to KRAS/MAPK inhibition in pancreatic cancer*
    Ofejiro Pereye, Washington University in St. Louis, St Louis, Missouri
  • 9:50 a.m. | Discussion / Q&A

break

10:15-10:45 a.m. | American Ballroom Foyer (4th Floor)

Stephenson Global Prize Award Presentation and Honorary Lecture

10:45 a.m.-12 p.m. | America Ballroom (4th Floor)

  • Stephenson Global Prize Lecture
    Frank McCormick, Helen Diller Family Comprehensive Cancer Center, San Francisco, California
view award announcement

lunch on own/ Free Time

12-2 p.m.

Plenary Session 6: Tumor Heterogeneity and Evolution

2-3:45 p.m. | America Ballroom (4th Floor)

Session Chair: Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina

  • 2:05 p.m. | The role of plasticity in tissue remodeling and tumor progression
    Dana Pe’er, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2:25 p.m. | The “viral-like” behavior of pancreatic cancer
    David T. Ting, Massachusetts General Hospital Cancer Center, Boston, Massachusetts
  • 2:45 p.m. | Deconstructing reciprocal tumor-host interactions in the pancreatic cancer microenvironment
    Claus Jorgensen, Cancer Research UK Manchester Institute, Manchester, England
  • 3:05 p.m. | HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity
    Sita Kugel, Fred Hutchinson Cancer Center, Seattle, Washington
  • 3:10 pm. | Functional dissection of the highly plastic basal cell state in pancreatic cancer*
    Anupriya Singhal, Memorial Sloan Kettering Cancer Center, New York, New York
  • 3:15 p.m. | Mapping and modulating epithelial-mesenchymal plasticity under RAS(ON) multi-selective inhibition in PDAC through lineage tracing and Perturb-seq*
    Julien Dilly, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 3:20 p.m. | Discussion / Q&A

Break

3:45-4 p.m. | American Ballroom Foyer (4th Floor)

Plenary Session 7: New Therapeutic Strategies

4-5:45 p.m. | America Ballroom (4th Floor)

Session Chair: Colin D. Weekes, Massachusetts General Hospital, Boston, Massachusetts

  • 4:05 p.m. | Targeting tumor-nerve interactions in pancreatic cancer
  • William L. Hwang, Massachusetts General Hospital, Boston, Massachusetts
  • 4:25 p.m. | Targeting crosstalk mechanisms supporting pancreatic cancer
    Christopher J. Halbrook, University of California, Irvine, California
  • 4:45 p.m. | ADCs for pancreatic cancer
    Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 5:05 p.m | pan-RAS-GTP inhibition relieves angiosuppression in PDAC by repressing Hedgehog paracrine signaling*
    Marie Hasselluhn, Herbert Irving Comprehensive Cancer Center, New York, New York
  • 5:10 p.m. | A model for the origins of transcriptional heterogeneity in human pancreatic ductal adenocarcinoma*
    Sabrina Ge, University of Toronto, Toronto, ON, Canada
  • 5:15 p.m. | Discussion / Q&A

poster session b/reception

6-9 p.m. | Essex Ballroom (3rd Floor)

Wednesday, October 1

CONTINENTAL BREAKFAST

7-8:30 a.m. | Essex Ballroom (3rd Floor)

Meet-the-Expert / Mentoring Roundtables Session

7:30-8:30 a.m. | Essex Ballroom (3rd Floor)

No pre-registration is required for this session. Attendance is on a first-come, first-served basis. Participants may rotate to as many tables as they like during the session, providing the opportunity to network and interact with a diverse cadre of experts.

Balancing Clinical and Research Responsibilities
Alice Wei		Conducting Translational Research: How to Get Started
Kevin Soares  
Balancing Clinical and Research Responsibilities
Neeha Zaidi  		How to Write a Grant
Jen Jen Yeh  
Choosing a Career Path: Academia v Industry
Colin Weekes  		Publishing Your Paper / Meet the AACR Editors
Alia Sajani, Michele Hartsough, and Harmony Turk  
Collaborating with Industry
Malika Singh  		Starting Your Lab
Edna Cukierman  
UK/EU Opportunities and Collaborations
Claus Jorgenson

cochair highlights

8:30-9 a.m. | America Ballroom (4th Floor)

  • 8 a.m. | Better options for pancreatic cancer patients today
    Susan Tsai, The Ohio State University Wexner Medical Center, Columbus, Ohio
  • 8:20 a.m. | Daily Preview

Plenary Session 8: Advances in Multimodality Care

9-10:25 a.m. | America Ballroom (4th Floor)

Session Chair: Alice Wei, Memorial Sloan Kettering Cancer Center, New York, New York

  • 9:05 a.m. | Vaccine therapy in pancreatic cancer
    Kevin C. Soares, Memorial Sloan Kettering Cancer Center, New York, New York
  • 9:25 a.m. | Trials and tribulations: Where radiotherapy fits in pancreatic cancer
    Nina Niu Sanford, University of Texas Southwestern Medical Center, Dallas, Texas
  • 9:45 a.m. | Integration of combinatorial vaccine immunotherapy for pancreatic cancer
    Neeha Zaidi, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 10:05 a.m. | Discussion / Q&A

break

10:25-10:55 a.m. | American Ballroom Foyer (4th Floor)

Plenary Session 9: Poster Spotlight Session – Oral Presentations

10:55 a.m.-11:55 a.m. | America Ballroom (4th Floor)

CLosing Remarks

11:55 a.m. | America Ballroom (4th Floor)